Matthew Golden is an Infectious Disease physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
325 9th Ave
Box 359777
Seattle, WA 981042420
Telephone
206-731-6829Registry record last updated 17 Dec 2012.
Clinical trials
- HIV Clinic-Based Intervention to Improve ART Adherence and Prevent HIV Transmission
Sponsor: Centers for Disease Control and Prevention
- Washington State Community Expedited Partner Treatment (EPT) Trial
Sponsor: University of Washington
- Assisted Partner Notification to Augment HIV Treatment and Prevention in Kenya
Sponsor: University of Washington
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gen-Probe, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
39.8%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor16%Tivicay85%Juluca15%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor12%Descovy68%Emtricitabine-Tenofovir Disop32%Part D<11 patients+ 4 more classes in this area
Cardiovascular
35.3%Statin13%Atorvastatin Calcium77%Rosuvastatin Calcium23%Part D<11 patientsBeta blocker8.5%Metoprolol Succinate53%Carvedilol24%Pindolol24%Part D<11 patients+ 3 more classes in this area
Nervous system
9.8%Gabapentinoids5.2%Gabapentin55%Pregabalin45%Part D<11 patientsSNRI2.7%Venlafaxine Hcl Er100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2000–2025 per NIH RePORTER. The latest:
- Evaluation of a Treponema pallidum transcription mediated amplification assay for Syphilis Screening
University of Washington
FY2025$1,094,147R01AI155442 - Evaluation of a Treponema pallidum transcription mediated amplification assay for Syphilis Screening
University of Washington
FY2024$138,876R01AI155442 - Evaluation of a Treponema pallidum transcription mediated amplification assay for Syphilis Screening
University of Washington
FY2023$706,468R01AI155442
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”